European Patent Office to Grant ToolGen, Inc. a patent on CRISPR-Cas9 system for genome editing
SEOUL, South Korea, July 31, 2018 (GLOBE NEWSWIRE) -- ToolGen, Inc. (KONEX 199800) announced today that on July 26, 2018 the European Patent Office (EPO) issued a Decision to Grant to ToolGen a European patent covering a CRISPR-Cas9 genome editing system adapted for mammalian cells.
CRISPR-Cas9 is a cutting-edge tool for genome editing in human cells, animals, and plants, widely used in biomedical research and biotechnology. CRISPR technology enables targeted genetic modifications in cells and whole organisms, which can lead to development of novel therapies and value-added crops and livestock.
Jongmoon Kim, Chief Executive Officer of ToolGen, commented, “We are committed to developing transformative therapeutics and agricultural products using our CRISPR-Cas9 genome editing system. This patent grant from the EPO begins to lay the groundwork for our intellectual property in Europe and further validates our research efforts. With this patent in hand, we intend to pursue additional IP applications and licensing partnerships worldwide.”
The European patent (number EP 2912175 B1) that was granted is entitled “Composition for cleaving a target DNA comprising a guide RNA specific for the target DNA and Cas Protein-encoding nucleic acid or Cas protein, and use thereof,” and lists ToolGen, Inc. as the applicant.
In addition to Europe, ToolGen is pursuing patent rights worldwide and has issued patents in South Korea and Australia. ToolGen has licensing partners for these patent rights in agriculture and clinical research.
ToolGen has one of the earliest filing dates for the use of CRISPR/Cas9 in mammalian systems, which is significant in first-to-file patent systems such as that of the EPO. ToolGen’s European patent is based on a patent application filed by ToolGen on October 23, 2012, and would cover key European countries including Austria, Denmark, France, Germany, Italy, Netherlands, Spain, Sweden, and United Kingdom.
The European patent can be opposed by interested parties within nine months of the publication of the decision to grant.
ToolGen, Inc. is a biotechnology company focused on the development and application of genome editing technologies. It creates and holds intellectual property rights for essential tools and technologies including CRISPR/Cas9 for editing the genetic information in microbial, plant, animal, and human cells. ToolGen’s mission is to translate the potential of its innovative platform technology into transformative products for biomedicine and agriculture. For more information, please visit www.toolgen.com.
This press release contains forward-looking statements. Forward-looking statements can be identified by words such as “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods.
Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, risks and uncertainties relating to intellectual property claims and challenges, uncertainties regarding the intellectual property protection for our technology and intellectual property belonging to third parties, uncertainties inherent in a highly competitive IP landscape, or company’s exposure to various contingencies, including those related to intellectual property protection.
Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Company – Seokjoong Kim +82-10-6776-7824
Media – Kirsten Thomas (508) 280-6592
Investors – Tram Bui (646) 536-7035
Upcoming Life Sciences Events
- January 2019
- San Francisco: Biotech Showcase
- San Francisco: RESI San Francisco 2019
- February 2019
- New York: BIO CEO & Investor Conference